Big Pharmas Back $300m Neglected Disease Fund
Cash For Projects 'Wall Street and Silicon Valley Pay Little Attention To'
Executive Summary
Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.
You may also be interested in...
Novartis, Takeda See Industry Better Prepared For Next Pandemic
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact
The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.